Furthermore, pending the outcome of the pivotal trial for [177Lu]Lu-PSMA (VISION trial; NCT03511664) in prostate cancer patients, it is anticipated that with positive results the translation to other solid cancers may be accelerated. Here, FOLH1 is linked to prostate carcinoma.